Floatz logo

Ebna1 C-Terminal/Lmp2 Chimeric Protein-Expressing Recombinant Modified Vaccinia Ankara Vaccine

Lymphoproliferative Disorder

Cancer Research UKvaccinePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

28 Active assets in the Lymphoproliferative Disorder cohort.

Asset / SponsorPhaseRating
Darbepoetin Alfa
Mayo Clinic
Phase 3BB
Epoetin Alfa
Mayo Clinic
Phase 3BB
Fludarabine
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 2BB
Cyclophosphamide
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 2BB
Baclofen
Alliance for Clinical Trials in Oncology
Phase 3BB

View all 50 →

Same molecule, other indications

Ebna1 C-Terminal/Lmp2 Chimeric Protein-Expressing Recombinant Modified Vaccinia Ankara Vaccine is also rated in:

Nonneoplastic ConditionDormant
CC
Indicative ·
47 / 100
View asset →
head and neck cancerDormant
CC
Indicative ·
42 / 100
View asset →
gastric cancerDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →